Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.480
+0.050 (3.50%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Innate Pharma Employees
Innate Pharma had 120 employees as of June 30, 2026. The number of employees decreased by 44 or -26.83% since the number was reported on December 31, 2025.
Employees
120
Change
-44
Growth
-26.83%
Revenue / Employee
$93,378
Profits / Employee
-$451,807
Market Cap
135.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 120 | -44 | -26.83% |
| Dec 31, 2025 | 164 | -17 | -9.39% |
| Dec 31, 2024 | 181 | 2 | 1.12% |
| Dec 31, 2023 | 179 | -32 | -15.17% |
| Dec 31, 2022 | 211 | -4 | -1.86% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| Molecular Partners AG | 134 |
| Acumen Pharmaceuticals | 61 |
| Armata Pharmaceuticals | 61 |
| Korro Bio | 57 |
| Anavex Life Sciences | 34 |
| Outlook Therapeutics | 17 |
IPHA News
- 7 days ago - Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround - Nasdaq
- 10 days ago - Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA) - Nasdaq
- 13 days ago - Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22 - Nasdaq
- 4 weeks ago - Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript - The Motley Fool
- 4 weeks ago - Innate Pharma Q2 Earnings Call Highlights - MarketBeat
- 4 weeks ago - Innate Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Innate Pharma Earnings release: Q2 2026 - Filings
- 4 weeks ago - Innate Pharma Earnings release: Q2 2026 - Filings